StoneWise
PrivateLast Round
Series B
Extension
Apr 12, 2021
Total Funding Raised
$120M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
StoneWise operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series B Extension round in April 2021.
StoneWise is a drug discovery company that provides an artificial intelligence drug discovery system designed to accelerate and improve the early stages of pharmaceutical development.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
StoneWise Comparables
Compare StoneWise with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MindRank | 87% | |
| Insilico Medicine | 78% | |
| Numerion Labs | 77% |
For institutional investors. Book with your work email.
StoneWise Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Apr 12, 2021 | ||||
| Series B | Apr 12, 2021 | ||||
| Series A Extension | Sep 15, 2020 | ||||
| Series A | Mar 16, 2020 | ||||
| Angel | Jul 1, 2019 |
For institutional investors. Book with your work email.
StoneWise Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hillhouse Investment | Series B Extension, Series A Extension, Series B |
| CDH Investments | Series B Extension, Series B |
| Legend Capital | Series B |
| Lightspeed China Partners | Series B |
| Susquehanna International Group | Series B Extension, Angel, Series B |
| Linear Capital | Series B Extension, Series A Extension, Series A, Series B |
| Eastern Bell Capital | Series B Extension, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Open roles increased to 10, representing 77% of headcount.
- Jul 13, 2026
Open roles increased to 8, 62% of headcount.
For institutional investors. Book with your work email.
StoneWise Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about StoneWise's valuation, stock price, and market status.
Is StoneWise a public or private company?
StoneWise is a private company.
What is the current stock price of StoneWise?
StoneWise is a private company, so its shares have no public market price. Caplight tracks StoneWise's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is StoneWise worth (valuation)?
Valuation information for StoneWise is not publicly available.
Can I buy StoneWise stock?
StoneWise shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was StoneWise's last funding round?
StoneWise's most recent funding round was Series B Extension on April 12, 2021.
Who are the main investors in StoneWise?
Key investors in StoneWise include Legend Capital, Greater Bay Area Homeland, Luminous Ventures.
Will StoneWise IPO soon?
No public IPO plans have been announced for StoneWise.
How can I track StoneWise secondary market activity?
Caplight tracks bids, offers, and trades in StoneWise's shares on secondary markets.